2017 ACVIM Forum Research Abstract Program

All dogs received at least 1 CRI treatment of cytarabine. Fourteen dogs also received at least 1 SQ treatment. The number of CRI treatments per dog was median of 5.5 (1 -38). Survival of all dogs was median of 258.5 days (61 -1312). Survival was not affected by age at diagnosis (P = 0.289), duration of clinical signs (P = 0.825), or sex (P = 0.413). There was a positive and significant correlation with number of CRI treatments and survival (r = 0.87, P = < 0.001). The number of SQ treatments did not affect survival time (r = À0.05, P = 0.819). In dogs with a relapse, there was a positive and significant correlation between number of CRI treatments and the longest period between clinical signs relapse (r = 0.82, P = 0.002).